Editas medicine stock price.

Editas Medicine Inc stock price (EDIT) NASDAQ: EDIT. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Editas Medicine Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53.During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01.The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks. Volume has increased on …CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ...

Editas Medicine's (NASDAQ: EDIT) lead candidate, EDIT-101, is a gene-editing therapy that targets a rare genetic disease called Leber congenital amaurosis 10, which leads to progressive blindness ...

The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD.

On Wednesday, Editas Medicine Inc [NASDAQ: EDIT] rose 3.76% to $8.84. The stock’s lowest price that day was $8.50, but it reached a high of $9.15 in the same session. During the last five days, there has been a surge of approximately 5.24%. Over the course of the year, Editas Medicine Inc shares have dropped approximately -0.34%.Editas Medicine Stock Forecast. ... According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts an ...11 Ago 2021 ... The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise ...By contrast, Bluebird and Editas shares both fell by over 50% over the first six months of 2022, while CRISPR's stock price stumbled by a noteworthy 20% during the first half of the year. Image ...Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $).

Beaten-down healthcare stocks Editas Medicine (EDIT-1.21%) and Bluebird Bio (BLUE 0.52%) could be two of the market's best short-squeeze candidates right now. Both companies have become top short ...

10.68 BATS BZX Real-Time Price As of 3:23pm ET +0.15 / +1.42% Today’s Change 6.08 Today ||| 52-Week Range 11.93 +20.41% Year-to-Date Quote Profile News Charts Forecasts Financials Shareholders...

Nov 17, 2023 · Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Mar 27, 2023 · Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ... Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... What happened. Shares of Editas Medicine ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics.Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85. The forecasts range from a low of $7.00 to a high of $30.00. The average ...Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.On June 15, Editas Medicine ( EDIT 3.66%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ...Editas Medicine, Inc. (EDIT) Stock Price, Quote, News & Analysis EDIT Editas Medicine, Inc. Stock Price & Overview 38.49K followers $10.53 -0.08 ( -0.75%) …

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geulah Livshits from Chardan Capital remains neutral on the stock ...You may have come across Amox Clav when visiting a doctor with the symptoms of an infection. Amox Clav is a combination medicine that may be used to treat a wide variety of infections.Check out our EDIT stock analysis, current EDIT quote, charts, and historical prices for Editas Medicine stockCurrent Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Dec 1, 2023 · 12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. Stock Quote. Change Volume 52 Week High 52 Week Low Dec 2, 2023 5:42 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. Upcoming Events EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update, December 2023. ... Editas Medicine, Inc. Phone: 617.401.0113 E-mail: [email protected] >> Main …Editas got a bump on Sept. 29 when Stifel analyst Dae Gon Ha increased his 12-month price target for Editas from $9 to $17 and upgraded his position on the biotech stock from hold to buy, saying ...

Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ...

Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Robinhood (HOOD 5.91%), in particular, makes this process a breeze with its stock slices option (useful for weighting) and commission-free trading. Put simply, you …This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...Feb 17, 2021 · Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... Editas Medicine (EDIT 2.28%) is on the cutting edge of CRISPR. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR ... Editas Medicine, Inc. (EDIT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Editas Medicine, Inc. | Nasdaq: EDIT | Nasdaq …Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis.What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ... Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ...

Jan 26, 2023 · Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...

Dec 1, 2023 · According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ...

Today's High Today's Low 52 Week High 52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. >> Main navigation. Research and Pipeline; CRISPR Gene EditingCurrent Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Editas Medicine's (NASDAQ: EDIT) lead candidate, EDIT-101, is a gene-editing therapy that targets a rare genetic disease called Leber congenital amaurosis 10, which leads to progressive blindness ...The decrease was driven by reduced headcount related expense, including stock compensation, and reduced legal costs. Upcoming Events Editas Medicine plans to participate in the following scientific and medical conference: American Society of Hematology (ASH) ... Chardan Cuts Price Target on Editas Medicine to $19 From $22, …11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... Nov 20, 2022 · Price as of December 1, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street. Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geulah Livshits from Chardan Capital remains neutral on the stock ...With Editas Medicine stock trading at $10.49 per share, the total value of Editas Medicine stock (market capitalization) is $856.76M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.Over the last month the Editas Medicine, Inc. (NASDAQ:EDIT) has been much stronger than before, rebounding by 72%.Meanwhile over the last three years the …

Editas Medicine Inc stock price (EDIT) NASDAQ: EDIT. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Editas Medicine Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Jan 13, 2022 · Shares of Editas Medicine (EDIT 3.76%) were tumbling 13% lower this week as of the market close on Thursday, ... Stock Advisor list price is $199 per year. Join Stock Advisor Jan 10, 2023 · In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00. Snap's stock is now far below its all-time high of close to $80 in 2021, but patient investors could see shares reach and exceed that price. Prosper Junior Bakiny has no position in any of the ...Instagram:https://instagram. investments under 10kstock symbol searchmtmvjob history for mortgage Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions. vaulted gold reviewsis blue cross blue shield good dental insurance Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. ... Shares of Editas Medicine (EDIT 2.28%) ... financial consultant firms Jun 28, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... The Editas Medicine stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.